BIIB News 343.04 09/02/2014 04:30:37 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 343.04 $BIIB

Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple

Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...

Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.

US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.

Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...

Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Business Wire - Tue Aug 26, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9th Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

Economic Data Fuel Another All-Time High For S&P 500
at Investor's Business Daily - Tue Aug 26, 2:36PM CDT
A big jump in durable goods orders and a strong reading on consumer confidence from the Conference Board fueled modest gains for the stock market Tuesday. The Dow Jones industrial average led the way, rising 0.3%. Exxon Mobil (XOM), UnitedHealth...

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Business Wire - Tue Aug 26, 7:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec's amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub). The ALS iHub is a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. Dr. Johns reports directly to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.

Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
CNW Group - Tue Aug 26, 7:00AM CDT
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions -

Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...

Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs
at Investor's Business Daily - Mon Aug 25, 1:54PM CDT
Major averages held on to decent gains with a little over one hour remaining in Monday's session. After topping the 2000 level, the S&P 500 rallied 0.5%; the Dow Jones industrial average also gained 0.5% while the Nasdaq tacked on 0.3%. Nasdaq volume...

Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...

Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.

Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.

Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 36

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 102

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 111

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 42

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 319

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Smart Waste Management Market Growth Insights

Updated Category News Views 124

Overview of the Smart Waste Management Market In recent years, the smart waste management market has garnered substantial attention, projected to transition from $2.2 billion in valuation to an impressive $8.3 billion. This surge reflects a remarkable compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. The driving force behind this growth stems from increasing...

Continue Reading
Exploring the Collaborative Spirit at the China-US Event

Updated Category News Views 150

Celebrating Cultural Connections The recent 'My China Album' event highlighted the importance of cultural exchanges between the United States and China, focusing on the shared journeys and experiences of citizens from both nations. Strengthening Relations through Understanding During this special occasion, the ambassador emphasized the collaborative spirit that can propel...

Continue Reading
Exciting New Active Adult Community Launches in Central Oregon

Updated Category News Views 143

Welcoming Active Adults to Dry Canyon Introducing Dry Canyon, an extraordinary gated community designed specifically for those aged 55 and better. This remarkable development offers active adults a perfect blend of resort-style living and scenic beauty, all nestled in the heart of Central Oregon. As part of this celebration, Lennar, a well-respected name among...

Continue Reading
XTI Aerospace Announces Upcoming Town Hall for Stakeholders

Updated Category News Views 153

XTI Aerospace Invites Stakeholders to Upcoming Town Hall Updates on Tri-Fan 600, Valkyrie AI and Vanguard Platform ENGLEWOOD, Colo. – XTI Aerospace, Inc. (NASDAQ: XTIA) is at the forefront of advancing vertical flight technologies. The company is making exciting progress with its next-generation vertical takeoff and landing (VTOL) aircraft, the TriFan 600. XTI Aerospace...

Continue Reading
Big Lots Launches Discounts and Donations for Vets in November

Updated Category News Views 47

Big Lots Supports Veterans and Active Military with November Campaigns Every November, Big Lots makes a concerted effort to give back to veterans and active military members. This initiative is a part of their commitment to recognizing the sacrifices made by those who serve our country. Highlighting their respect for military service, Big Lots introduces various discounts...

Continue Reading